One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
    • Chemicals & Materials
      • Advanced Materials
      • Bulk Chemicals
      • Coatings | Paints and Additives
      • Composites
      • Renewable | Speciality chemicals
    • Consumer Goods
      • Baby Products
      • Consumer Electronics
      • Consumer Packaging
      • Cosmetics & Personal Care
      • Homecare & Decor
      • Luxury & premium products
    • Energy and Power
      • Energy Efficiency and Conservation
      • Green | Renewable Energy
      • Non Renewable | Conventional Energy
      • Power Equipment and Devices
    • Life Science
      • Biotechnology
      • Diagnostics
      • Healthcare
      • Healthcare IT
      • Medical Devices & Supplies
      • Pharmaceuticals
    • Food and Beverage
      • Agriculture & Agri Products
      • Beverages
      • Food Ingredients
      • Food Services and Hospitality
      • Nutraceutical | Wellness Food
      • Processed & Frozen Foods
    • Automotive and Transportation
      • Automotive components
      • Automotive Logistics
      • Automotive systems and accessories
    • Information and Communications Technology
      • E Commerce and Outsourcing
      • Entertainment & Media
      • High Tech | Enterprise & Consumer IT
      • Information & Network Security
      • Mobility | Telecom & Wireless
      • Software and Services
    • Semiconductor and Electronics
      • Semiconductor Materials and Components
      • Display Technology
      • Electronics System and Components
      • Emerging technologies
      • Security and Surveillance
      • Sensors and Controls
    • Building and Construction
      • Construction Materials
      • HVAC
      • Residential Construction and Improvement
      • Roads & Highways
    • Manufacturing
      • Manufacturing Services
      • Heavy Manufacturing
      • Packaging
      • Engineering | Equipment and Machinery
  • Who Trust Us
  • [email protected]
  • +1 718 874 1545 (International)
  • +91 78878 22626 (Asia)

More Results

One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
    • Chemicals & Materials
      • Advanced Materials
      • Bulk Chemicals
      • Coatings | Paints and Additives
      • Composites
      • Renewable | Speciality chemicals
    • Consumer Goods
      • Baby Products
      • Consumer Electronics
      • Consumer Packaging
      • Cosmetics & Personal Care
      • Homecare & Decor
      • Luxury & premium products
    • Energy and Power
      • Energy Efficiency and Conservation
      • Green | Renewable Energy
      • Non Renewable | Conventional Energy
      • Power Equipment and Devices
    • Life Science
      • Biotechnology
      • Diagnostics
      • Healthcare
      • Healthcare IT
      • Medical Devices & Supplies
      • Pharmaceuticals
    • Food and Beverage
      • Agriculture & Agri Products
      • Beverages
      • Food Ingredients
      • Food Services and Hospitality
      • Nutraceutical | Wellness Food
      • Processed & Frozen Foods
    • Automotive and Transportation
      • Automotive components
      • Automotive Logistics
      • Automotive systems and accessories
    • Information and Communications Technology
      • E Commerce and Outsourcing
      • Entertainment & Media
      • High Tech | Enterprise & Consumer IT
      • Information & Network Security
      • Mobility | Telecom & Wireless
      • Software and Services
    • Semiconductor and Electronics
      • Semiconductor Materials and Components
      • Display Technology
      • Electronics System and Components
      • Emerging technologies
      • Security and Surveillance
      • Sensors and Controls
    • Building and Construction
      • Construction Materials
      • HVAC
      • Residential Construction and Improvement
      • Roads & Highways
    • Manufacturing
      • Manufacturing Services
      • Heavy Manufacturing
      • Packaging
      • Engineering | Equipment and Machinery
  • Who Trust Us
Home ➤ Life Science ➤ Therapeutics ➤ mRNA Therapeutics Market
mRNA Therapeutics Market
mRNA Therapeutics Market
Published date: Oct 2024 • Formats:
Request Sample Schedule a Call
  • Home ➤ Life Science ➤ Therapeutics ➤ mRNA Therapeutics Market

Global mRNA Therapeutics Market By Type (Prophylactic Vaccines and Therapeutic Vaccines), By Application (Oncology, Infectious Diseases, Respiratory Diseases, and Others), By End-user (Hospitals & Clinics, Research Organizations, and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

  • Published date: Oct 2024
  • Report ID: 131238
  • Number of Pages: 342
  • Format:
  • Overview
  • Table of Contents
  • Major Market Players
  • Request a Free Sample
  • Quick Navigation

    • Report Overview
    • Key Takeaways
    • By Type Analysis
    • By Application Analysis
    • By End-user Analysis
    • Key Market Segments
    • Drivers
    • Restraints
    • Opportunities
    • Impact of Macroeconomic / Geopolitical Factors
    • Latest Trends
    • Regional Analysis
    • Key Players Analysis
    • Recent Developments
    • Report Scope

    Report Overview

    Global mRNA Therapeutics Market size is expected to be worth around US$ 40.3 Billion by 2033 from US$ 18.5 Billion in 2023, growing at a CAGR of 8.1% during the forecast period 2024 to 2033.

    Growing interest in mRNA therapeutics is transforming the landscape of modern medicine, driven by the success of mRNA-based vaccines and the potential to treat a wide range of diseases, including cancer, infectious diseases, and rare genetic disorders. The ability of mRNA therapies to instruct cells to produce specific proteins makes them a versatile platform for therapeutic development.

    In 2024, Moderna received $176 million in federal funding to develop mRNA vaccines targeting bird flu, signaling strong governmental support for pandemic preparedness. The expanding application of mRNA in oncology is also evident, as CureVac partnered with MD Anderson in 2024 to advance mRNA-based cancer vaccines. BioNTech SE’s acquisition of InstaDeep Ltd. in early 2023, aimed at integrating AI-driven drug discovery into mRNA therapeutic development, underscores the growing importance of artificial intelligence in this market.

    Furthermore, Moderna’s establishment of a new mRNA manufacturing facility in early 2024 demonstrates the industry’s commitment to scaling production capacity. Opportunities for personalized medicine, rapid vaccine development, and novel treatments continue to drive innovation and investment in the mRNA therapeutics sector.

    mRNA Therapeutics Market Size

    Key Takeaways

    • Market Size: Global mRNA Therapeutics Market size is expected to be worth around US$ 40.3 Billion by 2033 from US$ 18.5 Billion in 2023.
    • Market Growth: The market growing at a CAGR of 8.1% during the forecast period 2024 to 2033.
    • Type Analysis: The prophylactic vaccines held a significant share of 61.4% due to the increasing incidence of cancer globally and the need for more targeted therapies.
    • Application Analysis: The oncology segment led in 2023, claiming a market share of 42.7% owing to its effectiveness in preventing infectious diseases.
    • End-Use Analysis: The hospitals & clinics segment had a tremendous growth rate, with a revenue share of 54.5% owing to the increasing demand for specialized treatment options.
    • Regional Analysis: In 2023, North America dominated the market with the highest revenue share of 40.4%

    By Type Analysis

    The prophylactic vaccines held a significant share of 61.4% due to the increasing incidence of cancer globally and the need for more targeted therapies. mRNA-based treatments offer a promising approach for developing personalized cancer vaccines, which are expected to significantly enhance immune responses against tumor cells. Ongoing advancements in mRNA technology, including its ability to encode for specific antigens and promote precise immune modulation, are likely to drive the adoption of these therapies in oncology.

    Furthermore, the growing investment in cancer research and clinical trials involving mRNA-based approaches is anticipated to accelerate progress. The ability to rapidly develop treatments in response to specific cancer types, alongside the potential for fewer side effects compared to conventional chemotherapy, is estimated to further support growth in this segment.

    By Application Analysis

    The oncology segment led in 2023, claiming a market share of 42.7% owing to its effectiveness in preventing infectious diseases. The success of mRNA vaccines in addressing the COVID-19 pandemic has highlighted their potential for rapid development and scalability. This breakthrough has prompted further research into vaccines for a range of other infectious diseases, including influenza, HIV, and Zika virus, which are likely to drive demand for prophylactic mRNA vaccines.

    Additionally, mRNA technology allows for faster adaptation to emerging viral strains, enhancing the speed of vaccine development. The growing emphasis on pandemic preparedness and global immunization programs is projected to further support the expansion of this segment.

    By End-user Analysis

    The hospitals & clinics segment had a tremendous growth rate, with a revenue share of 54.5% owing to the increasing demand for specialized treatment options. Hospitals and clinics are likely to play a crucial role in the administration of mRNA-based therapies, particularly in oncology and infectious diseases, where personalized and precision treatments are essential.

    The growing availability of clinical trial programs and advanced healthcare infrastructure in hospitals is anticipated to support the widespread adoption of these therapies. Additionally, the need for professional oversight in administering mRNA vaccines and therapies, along with post-treatment care, is likely to drive the reliance on hospitals and clinics as the primary healthcare providers for these innovative treatments.

    mRNA Therapeutics Market Share

    Key Market Segments

    By Application

    • Oncology
    • Infectious Diseases
    • Respiratory Diseases
    • Others

    By Type

    • Prophylactic Vaccines
    • Therapeutic Vaccines

    By End-user

    • Hospitals & Clinics
    • Research Organizations
    • Others

    Drivers

    Increasing vaccine development drives the mRNA therapeutics market

    Increasing vaccine development initiatives significantly propel the growth of the mRNA therapeutics market. Companies continue to expand their research efforts to address a broader range of diseases. For instance, in September 2023, Moderna, Inc. advanced its mRNA research into oncology, respiratory conditions, and rare diseases, a move expected to enhance its revenue streams.

    Moreover, in August 2023, CureVac began dosing participants in a Phase 2 study of modified COVID-19 mRNA vaccine candidates in collaboration with GSK Plc. The growing demand for vaccines to combat emerging diseases has led to substantial investment in the mRNA field. This rise in research and development activities is anticipated to accelerate breakthroughs in vaccine technology, particularly for infectious diseases and cancer.

    Restraints

    High manufacturing cost restrains the mRNA therapeutics market

    High manufacturing costs are anticipated to hamper the growth of the mRNA therapeutics market. The production process for mRNA-based therapies involves complex steps that require advanced technology, specialized equipment, and rigorous quality control, all of which contribute to increased operational expenses. These high costs often translate into expensive treatment options, making them less accessible, particularly in low-income regions.

    Additionally, maintaining the cold chain logistics for mRNA products further inflates overall expenses, as these therapies typically require ultra-cold storage conditions. The financial burden associated with producing and distributing these therapies is expected to impede broader market adoption and limit affordability for many patients, thereby restricting market expansion.

    Opportunities

    Increasing R&D activities create opportunities for the mRNA therapeutics market

    Growing research and development (R&D) activities present significant opportunities for the mRNA therapeutics market. In November 2023, Sanofi inaugurated a new mRNA research facility at Griffith University, projected to drive innovation in developing novel therapeutics. These R&D initiatives aim to explore the potential of mRNA technology in addressing a wide array of diseases, including cancer, infectious diseases, and genetic disorders.

    Increased investment in developing next-generation mRNA-based therapies has opened new avenues for treating previously untreatable conditions. The rapid advancements in mRNA technology, coupled with expanding clinical trials, are anticipated to support the market’s long-term growth. Rising collaboration between pharmaceutical companies and research institutions further strengthens this opportunity, fostering breakthroughs in personalized medicine and targeted therapies.

    Impact of Macroeconomic / Geopolitical Factors

    Global economic and geopolitical conditions significantly influence the mRNA therapeutics industry. Economic downturns, such as inflation and rising interest rates, increase the cost of research and development, potentially slowing down innovation and clinical trials. Trade restrictions and regulatory hurdles, especially in politically unstable regions, further complicate the global supply chain, limiting access to critical raw materials and technology.

    Conversely, increased government investment in healthcare, particularly in response to pandemics, has positively impacted the development of mRNA-based vaccines and treatments. Additionally, favorable public health policies and strategic partnerships with international regulatory bodies create a more conducive environment for faster product approvals. As healthcare systems prioritize innovative therapies, the market for mRNA-based treatments is expected to experience sustained growth.

    Latest Trends

    Rising Collaborations and Partnerships Driving mRNA Therapeutics Market Growth

    Increasing collaborations and partnerships among biotech companies and research organizations are projected to drive the growth of the mRNA therapeutics market. In August 2023, Gritstone bio, Inc. and Genevant Sciences entered an agreement that leverages Genevant’s advanced lipid nanoparticle platform to enhance delivery of nucleic acids.

    Similarly, in September 2023, BioNTech SE partnered with the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate the development of an mRNA-based Mpox vaccine. These partnerships aim to advance the efficacy and delivery of mRNA-based treatments and vaccines. As more companies collaborate to share technology and expertise, the pace of innovation is expected to accelerate, creating a competitive market landscape and contributing to the long-term growth of the industry.

    Regional Analysis

    North America is leading the MRNA Therapeutics Market

    North America dominated the market with the highest revenue share of 40.4% owing to advancements in COVID-19 vaccines and expanding applications of mRNA technology in other therapeutic areas. One significant milestone occurred in September 2023, when BioNTech and Pfizer received U.S. FDA approval for a new formulation of their mRNA-based COVID-19 vaccine, COMIRNATY, for the 2023-2024 season, approved for individuals aged 12 and older.

    This regulatory achievement has further reinforced the potential of mRNA technology in preventive medicine. Additionally, increased investment in research and development, as well as growing public and healthcare professional acceptance of mRNA therapies for various conditions beyond COVID-19, have played a crucial role in driving market expansion in North America.

    The Asia Pacific region is expected to experience the highest CAGR during the forecast period

    Asia Pacific is expected to grow with the fastest CAGR owing to increasing collaborations and investment in biotechnology. In November 2023, Moderna, Inc., in partnership with several Australian organizations, launched a new mRNA platform aimed at advancing messenger RNA-based medicines. This initiative is expected to accelerate research and development in the field, particularly in areas such as cancer therapies and rare diseases.

    The region’s expanding healthcare infrastructure, coupled with growing interest in innovative treatments, is likely to support the broader adoption of mRNA-based therapies. Additionally, government initiatives to strengthen biotech capabilities are projected to further stimulate growth, making Asia Pacific a key region for mRNA advancements.

    mRNA Therapeutics Market Region

    Key Regions and Countries

    North America

    • US
    • Canada

    Europe

    • Germany
    • France
    • The UK
    • Spain
    • Italy
    • Russia
    • Netherland
    • Rest of Europe

    Asia Pacific

    • China
    • Japan
    • South Korea
    • India
    • Australia
    • New Zealand
    • Singapore
    • Thailand
    • Vietnam
    • Rest of APAC

    Latin America

    • Brazil
    • Mexico
    • Rest of Latin America

    Middle East & Africa

    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of MEA

    Key Players Analysis

    The major players in the mRNA therapeutics market are actively engaged in the development and introduction of innovative products, as well as implementing strategic initiatives aimed at enhancing their competitive positioning. Key players in the mRNA therapeutics market drive growth by advancing innovative research and development initiatives, particularly in areas like oncology and infectious diseases.

    They form strategic partnerships with pharmaceutical companies and research institutions to enhance their technological capabilities and accelerate product pipelines. Expanding manufacturing capacities ensures they meet the increasing demand for these therapies.

    Additionally, companies focus on securing regulatory approvals and launching clinical trials to demonstrate efficacy and safety. They also invest in expanding their global reach, targeting both established and emerging markets for greater market penetration.

    Top Key Players

    • Moderna, Inc.
    • Ethris GMBH
    • Etherna Immunotherapies
    • Curevac AG
    • CSL Limited
    • CRISPR Therapeutics AG
    • BioNTech SE
    • AstraZeneca plc.
    • Argos Therapeutics Inc.
    • Arcturus Therapeutics

    Recent Developments

    • In January 2023, BioNTech SE entered into a strategic collaboration with the UK government to provide personalized mRNA cancer immunotherapies for up to 10,000 patients by 2030. This collaboration has had a positive impact on the company’s revenue and demonstrates the expanding application of mRNA technology beyond infectious diseases, supporting the growth of the mRNA therapeutics market.
    • In December 2022, CSL Limited announced that its subsidiary, CSL Seqirus, finalized a global collaboration and license agreement with Arcturus Therapeutics Holdings Inc. The agreement grants access to Arcturus’ late-stage self-amplifying mRNA (sa-mRNA) vaccine platform, which recently reported positive results in a Phase III COVID-19 vaccine efficacy study. This collaboration enhances CSL’s position in the mRNA therapeutics market, leveraging new technology that has shown effectiveness in preventing infection and severe disease, contributing to market growth.
    • In December 2022, Moderna, Inc. received emergency use authorization (EUA) from the U.S. FDA for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, for children aged six months to five years. This authorization, based on a booster dose containing mRNA encoding for both the BA.4/BA.5 variant and the original SARS-CoV-2 strain, highlights the ongoing advancements in mRNA vaccine development, reinforcing the role of mRNA technology in responding to emerging health threats and contributing to the growth of the mRNA therapeutics market.

    Report Scope

    Report Features Description
    Market Value (2023) USD 18.5 Billion
    Forecast Revenue (2033) USD 40.3 Billion
    CAGR (2024-2033) 8.1%
    Base Year for Estimation 2023
    Historic Period 2018-2022
    Forecast Period 2024-2033
    Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments
    Segments Covered By Type (Prophylactic Vaccines and Therapeutic Vaccines), By Application (Oncology, Infectious Diseases, Respiratory Diseases, and Others), By End-user (Hospitals & Clinics, Research Organizations, and Others)
    Regional Analysis North America – US, Canada; Europe – Germany, France, The UK, Spain, Italy, Russia, Netherlands, Rest of Europe; Asia Pacific – China, Japan, South Korea, India, Australia, New Zealand, Singapore, Thailand, Vietnam, Rest of APAC; Latin America – Brazil, Mexico, Rest of Latin America; Middle East & Africa – South Africa, Saudi Arabia, UAE, Rest of MEA
    Competitive Landscape Moderna, Inc., Ethris GMBH, Etherna Immunotherapies, Curevac AG, CSL Limited , CRISPR Therapeutics AG, BioNTech SE, AstraZeneca plc., Argos Therapeutics Inc., and Arcturus Therapeutics.
    Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements.
    Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)
    mRNA Therapeutics Market
    mRNA Therapeutics Market
    Published date: Oct 2024
    add_shopping_cartBuy Now get_appDownload Sample
    keyboard_arrow_up
    • Moderna, Inc.
    • Ethris GMBH
    • Etherna Immunotherapies
    • Curevac AG
    • CSL Limited
    • CRISPR Therapeutics AG
    • BioNTech SE
    • AstraZeneca plc.
    • Argos Therapeutics Inc.
    • Arcturus Therapeutics
  • settingsSettings

Related Reports

  • CAR-T Cell Therapies Market
  • Digital Therapeutics Market
  • Oxygen Therapy Market
  • Venous Stents Market
  • Acute Ischemic Stroke Therapeutics Market
  • Compression Therapy Market
  • Peptide Therapeutics Market
  • Brain Implants Market
  • Gout Therapeutics Market
  • Sickle Cell Disease Treatment Market

Our Clients

  • Our Clients
Inquiry Before Buying

mRNA Therapeutics Market
  • 131238
  • Oct 2024
    • ★★★★★
      ★★★★★
    • (142)
add_shopping_cart Buy Now
Trusted by more than 17382 organizations globally
  • Client Logo
  • Client Logo
  • Client Logo
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$6,000
$3,999
USD / per unit
save 24%
Multi User
$8,000
$5,999
USD / per unit
save 28%
Corporate User
$10,000
$6,999
USD / per unit
save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 3,999) Buy Now ($ 5,999) Buy Now ($ 6,999)
  • location_on420 Lexington Avenue, Suite 300 New York City, NY 10170,
    United States
  • phone+1 718 874 1545 (International)
  • phone+91 78878 22626 (Asia)
  • email[email protected]
  • Facebook Logo
  • Twitter Logo
  • LinkedIn Logo
Find Help
  • Contact Us
  • How to Order
Legal
  • Privacy Policy
  • Refund Policy
  • Frequently Asked Questions
  • Terms and Conditions
Explore
  • About Us
  • All Reports
  • All Sectors
  • Infographics
  • Statistics and Facts
  • Companies
Secured Payment Options
Secured Payment Options

© 2025 Market.Us. All Rights Reserved.